Loading...
•
Jun 30, 2024
Merck Q2 2024 Earnings Report
Merck's Q2 2024 financial results were announced, showcasing strong momentum and significant milestones including the launch of WINREVAIR.
Key Takeaways
Merck reported strong Q2 2024 results, with GAAP EPS at $2.14 and non-GAAP EPS at $2.28. The company highlighted the launch of WINREVAIR and progress in its pipeline.
GAAP EPS was $2.14 for the second quarter of 2024.
Non-GAAP EPS was $2.28 for the second quarter of 2024.
WINREVAIR was launched in the U.S. with over 1,000 patients receiving the treatment by the end of June.
FDA approved KEYTRUDA in combination with chemotherapy for certain patients with endometrial carcinoma.
Merck
Merck
Merck Revenue by Segment
Revenue by Segment
Pharmaceutical Revenue
CapyFin.comAnimal Health Revenue
CapyFin.com Forward Guidance
Merck is raising and narrowing its full-year sales outlook and now expects its full-year sales to be between $63.4 billion and $64.4 billion. Merck now expects its full-year non-GAAP EPS to be between $7.94 and $8.04.
Positive Outlook
- Strong global demand for key growth products, particularly in oncology.
- Raising and narrowing its full-year sales outlook.
- Full-year sales to be between $63.4 billion and $64.4 billion.
- Full-year non-GAAP EPS to be between $7.94 and $8.04.
- Inflation-related price increases are expected to offset the devaluation of the Argentine peso.
Challenges Ahead
- Negative impact of foreign exchange of approximately 3 percentage points.
- Approximately 2 percentage points of the negative impact of foreign exchange is due to the devaluation of the Argentine peso.
- Unfavorable impact related to the one-time charge for the acquisition of EyeBio, which is not tax deductible.
- Negative impact of foreign exchange of more than $0.30 per share.
- Outlook does not assume any additional significant potential business development transactions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income